BERYL DRUGS LTD.
Latest filings
- Compliance certificates filed for quarter ended Sept 30, 2026 · Compliance
- Beryl Drugs files non applicability certificate under Reg 57(5) for Sep 2026 quarter · Compliance
- Trading window closed ahead of Q2 FY2027 results · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures pharmaceutical products including IV fluids, oral solid doses, and PP Bottle and FFS (Form Fill Seal) products, sold to distributors and end-markets. Distribution for PP Bottle and FFS products in Maharashtra, Gujarat and exports was handed to Aminova Infusions Pvt Ltd under a ₹5 crore related-party arrangement running from January 2026, representing about 13.30% of annual consolidated turnover. Revenue in FY26 was ₹18.82 crore and net profit was ₹0.4248 crore, with the year hit by a manufacturing stop order from the Food and Drugs Administration, Madhya Pradesh in January 2025 that suspended the Blow Fill Seal (BFS) section until November 2025, contributing to a revenue decline of roughly 14.4% versus FY25. Materials account for 55.8% of revenue, employee cost 13.4%, other opex 24.4%, depreciation 7.9%, and capex was 20.3% of revenue, pointing to an asset-light manufacturing model. Listed on BSE with 50.71 lakh shares outstanding and not classified as a Large Corporate under SEBI thresholds.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from BERYL DRUGS LTD.'s filed financials and exchange disclosures
What does BERYL DRUGS LTD. do?
BERYL DRUGS LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.
Is BERYL DRUGS LTD. profitable?
Yes. Over the trailing twelve months BERYL DRUGS LTD. reported a net profit of ₹0.42 Cr on revenue of ₹19 Cr.
Does BERYL DRUGS LTD. pay a dividend?
Not in the latest reported year — BERYL DRUGS LTD.'s dividend payout for FY26 was nil.
Is BERYL DRUGS LTD. debt-free?
No. It reported borrowings of ₹2.39 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹2.12 Cr after cash. Debt stands at 0.24× equity. That is higher than 62% of its 166 Pharmaceuticals peers.
Is BERYL DRUGS LTD. expensive compared with its peers?
On trailing P/E, BERYL DRUGS LTD. ranks 79 of 158 in Pharmaceuticals — cheaper than 50% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.
How much does the BERYL DRUGS LTD. share price move in a day?
On a typical session BERYL DRUGS LTD. moves 2.41% — that is the median absolute close-to-close move across its last 262 trading days. MarketPing measures each filing's price reaction against it.
Where can I track BERYL DRUGS LTD.'s announcements?
Every NSE and BSE filing by BERYL DRUGS LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.